reports
- Jonathan Moreland
Moody's Ratings withdraws Steelcase's CFR following acquisition by HNI
Moody's Ratings (Moody's) withdrew Steelcase Inc.'s (Steelcase) Ba1 Corporate Family (CFR), Ba1-PD Probability of Default Rating (PDR), and the SGL-1 speculative grade liquidity rating. The Ba2 rating on Steelcase's senior unsecured notes due 2029 remains unchanged and the outlook is stable. In addi...
Catalyst Pharmaceuticals Inc: 1 director
A director at Catalyst Pharmaceuticals Inc sold/sold after exercising options 26,746 shares at 23.253USD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company'...
- Jonathan Moreland
GLP GLOBAL PARTNERS LP
CLFD CLEARFIELD INC.
CDXS CODEXIS
NB NIOCORP DEVELOPMENTS LTD
QTA QUATERRA RESOURCES INC.
WVE WAVE LIFE SCIENCES
DIS THE WALT DISNEY COMPANY
ELAN ELANCO ANIMAL HEALTH INC.
MIDD THE MIDDLEBY CORPORATION
AMCR AMCOR PLC
RZLT REZOLUTE
ZNTL INC.
BMEA ZENTALIS PHARMACEUTICALS
NRDY BIOMEA FUSION
KVUE INC.
PROP NERDY INC.
NEXT KENVUE INC
SPRU PRAIRIE OPERATING CO.
MXF NEXTSOURCE MATERIALS INC.
GF SPRUCE POWER HOLDING CORP
AFCG THE MEXICO FUND
SI INC.
SEVN THE NEW GERMANY FUND
INC.
AFC GAMMA
INC.
SHOULDER INNOVATIONS INC
SEVEN HILLS REALTY TRUST
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan...
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference CORAL GABLES, Fla., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO of Catalyst, along with other members of Catalyst's management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday...
Lesaka Webcast and Conference Call to Review Second Quarter 2026 Resul...
Lesaka Webcast and Conference Call to Review Second Quarter 2026 Results JOHANNESBURG, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (NASDAQ: LSAK, JSE: LSK) ("Lesaka") today announced it will release second quarter 2026 results after the U.S. market close on February 4, 2026. Lesaka management will host a presentation webcast and conference call on February 5, 2026, at 8:00am EDT (3:00pm SAST), followed by a live question and answer session for analysts and investors. Webcast Registration Link to access the results webcast: Participants using the webcast will be able to...
Catalyst Pharmaceuticals to Participate in the Bank of America CNS The...
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference CORAL GABLES, Fla., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Bank of America CNS Therapeutics Virtual Conference on Mo...
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-...
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2025 Deloitte Technology Fast 500™ Attributes 249% Revenue Growth to Portfolio Momentum and Focused Execution CORAL GABLES, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced it ranked 304 on the ™, a ranking of the 500 fastest-growing tec...
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthca...
Catalyst Pharmaceuticals to Participate in Citi’s 2025 Global Healthcare Conference CORAL GABLES, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in Citi’s 2025 Global Healthcare Conference in Miami on Tuesday, December 2, 20...
Moody's Ratings corrects website display for CUSIP 858155AE4
Moody's Ratings (Moody's) has corrected the display on its websites to reflect that CUSIP 858155AE4 is issued by Steelcase Inc., rated Ba2. Due to an internal administrative error, this CUSIP was incorrectly linked to a different issuer. This publication does not announce a credit rating action. F...
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results ...
Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance to between $565 Million and $585 Million, Reflecting Better than Originally Forecasted Performance Recently Announced Share Repurchase Program of up to $200 Million, Signaling Confidence in Long-term Outlook Conference Call and Webcast to be Held on Thursday, November 6, 2025, at 8:30 AM E...
Lesaka’s Q1 FY2026 Results: Lesaka achieves Q1 FY2026 guidance and rea...
Lesaka’s Q1 FY2026 Results: Lesaka achieves Q1 FY2026 guidance and reaffirms FY2026 outlook JOHANNESBURG, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (Nasdaq: LSAK; JSE: LSK) today released results for the first quarter of fiscal 2026 (“Q1 2026”). Q1 2026 performance1:All growth rates are year-on-year between Q1 FY2026 and Q1 FY2025. Revenue of $171.5 million (ZAR 3.0 billion) up 10% in ZAR.Net Revenue2 of $86.6 million (ZAR 1.5 billion), up 45% in ZAR.Operating Income of $0.4 million (ZAR 6.7 million), improved from a loss of $0.1 million (ZAR 0.3 million).Net Loss of $...
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to...
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work CORAL GABLES, Fla., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named as one of the BioSpace 2026 Best Places to Work for the second consecutive year, ranking 13 among 30 U.S. employers in the small company category. "We are honored to be na...
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare...
Catalyst Pharmaceuticals to Participate in Jefferies Global Healthcare Conference CORAL GABLES, Fla., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Rich Daly, President and CEO, along with other members of Catalyst's management team, will participate in the Jefferies Global Healthcare Conference in London on Monday, November 17, 2...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Nuveen Floating Rate Income Fund and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 16 October 2025 in which we reassessed the appropriateness of the ratings ...
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Result...
Catalyst Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 5, 2025 The Company will Host a Conference Call and Webcast on Thursday, November 6, 2025, at 8:30 AM ET CORAL GABLES, Fla., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its third quarter 2025 financial results after the market c...
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientifi...
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences CORAL GABLES, Fla., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that data developed by or in conjunction with the company will be presented at several upcoming scientific conferences, details of which are listed below. "At Catalyst, everything begins with patients. ...
Lesaka Webcast and Conference Call to Review First Quarter 2026 Result...
Lesaka Webcast and Conference Call to Review First Quarter 2026 Results JOHANNESBURG, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Lesaka Technologies, Inc. (NASDAQ:, JSE: LSK) ("Lesaka") today announced it will release first quarter 2026 results after the U.S. market close on November 5, 2025. Lesaka management will host a presentation webcast and conference call on November 6, 2025, at 8:00am EDT (3:00pm SAST), followed by a live question and answer session for analysts and investors. Webcast Registration Link to access the results webcast: Participants using the webcast will be able to submit...
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Progr...
Catalyst Pharmaceuticals Announces $200 Million Share Repurchase Program CORAL GABLES, Fla., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines for people living with rare and difficult-to-treat diseases, today announced that its Board of Directors has authorized a new share repurchase program to repurchase up to $200 million of shares of Catalyst's outstanding common stock between October 1, 2025, and December 31, 202...
PBF Energy Inc: 2 directors
Two Directors at PBF Energy Inc sold after exercising options/sold 110,000 shares at between 34.000USD and 34.134USD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.